Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

New Lyme Disease Diagnosis from Pharmasan Could Help 300,000 Americans
  • USA - English


News provided by

Meno Center for Advanced Medicine

May 27, 2014, 03:00 ET

Share this article

Share toX

Share this article

Share toX

Dr. Mark Menolascino MD, MS, ABIHM, ABAARM, IFMCP
Dr. Mark Menolascino MD, MS, ABIHM, ABAARM, IFMCP

Would America tolerate an HIV test that was wrong half of the time?

Post this

Jackson Hole, WY (PRWEB) May 27, 2014 -- May is Lyme disease awareness month, millions of Americans just spent Memorial Day weekend outdoors and the creepy, blood-sucking ticks that transmit the disease are at their peak life cycle right now. The timing is perfect to raise awareness of iSpot Lyme™, a dramatically improved clinical diagnosis developed by Pharmasan Labs for detecting Lyme disease. In most diseases, diagnosis plays second fiddle to treatment, but in the case of Lyme disease, diagnosis has been the biggest hurdle in an epidemic disease that is estimated to infect more people than AIDS, West Nile Virus, and Avian Flu combined.

The tick-borne Lyme disease is one of our country’s most mysterious maladies: widespread, hard to detect and hard to treat in its later stages. To put the difficulty in Lyme disease diagnosis into perspective, in 2011 the Centers for Disease Control and Prevention (CDC) reported nearly 32,500 new cases in the United States. While not a terrifying number on its own (unless a loved one happens to be one of them), a study reported in the New England Journal of Medicine estimated that, due to the difficulty in diagnosis, the actual number could be as much as 10 times higher with over 300,000 Americans suffering the diverse symptoms of the disease.

Improved diagnosis is a significant breakthrough because when the disease eludes clinical diagnosis in the early stages, it becomes dramatically more difficult to treat and the symptoms become exponentially more debilitating. The traditional testing methods utilize antiquated B cell methods, the antibody-based Enzyme Linked Immunosorbent Assay (ELISA) and Western Blot (WB). At best, these tests have a sensitivity of 50% in the early infection and less in later stages of the disease, as well as over 50% false negative results with the worst outcome of all - untreated patients.

iSpot Lyme™ is a variation on the currently used T-cell-based ELISPOT assay detection method. It improves upon previous detection methods by an astronomical margin with a sensitivity of 84% and specificity of 94% for the detection of Lyme.

“This is a total game changer,” said Mark Menolascino MD, MS, ABIHM, ABAARM, IFMCP and the Medical Director for The Meno Clinic Center for Advanced Medicine in Jackson Hole, after attending the Symposium on Tick-borne diseases in Cambridge, Maryland this month. “Would America tolerate an HIV test that was wrong half of the time? It (iSpot Lyme™) is as significant as if the HIV test used until now detected about 50% of the cases, and then a new test for HIV raised the sensitivity of detection to nearly 100% - essentially never missing the diagnosis.”

Symptoms of Lyme disease can include fatigue, arthritis-like joint pain and stiffness, headaches, tingling and shooting pain and rash. In its later stages, which are increasingly difficult to treat, symptoms include weakness, paralysis, agonizing joint pain, nervous system problems, inflammation of the brain causing cognitive dysfunction, shortness of breath, inflammation of the heart causing palpitations and arrhythmias, fibromyalgia and Chronic Fatigue Syndrome.

The initial tick bite may be detected, and reveal a telltale bull’s-eye rash around the bite site, but more than half the people diagnosed with Lyme disease don’t remember ever being bitten by a tick and half of those infected don’t develop the telltale rash, making self-diagnosis difficult. This also prevents physicians from being inclined to aggressively treat initial infections that ‘don’t fit the book’. Lyme disease has been called “the great imitator” because of its tendency to mimic symptoms of other diseases, leading physicians to incorrectly diagnose the disease and dooming patients to years of suffering and ineffective treatments.

While the numbers of victims of Lyme disease are staggering, the treatment is generally effective – at least in the early stages – giving Lyme disease the potential to be a low-hanging fruit in the world of disease control. Unlike many battles with disease waged by medical professionals and scientists where treatment is the missing piece, Lyme disease is a battle of diagnosis, making increased awareness and iSpot Lyme™ powerful weapons in the war against disease.

Dr. Mark Menolascino trained as a traditional Internal Medicine Specialist and achieved four board certifications and a dual Masters degree in Pharmacology/Immunology as well as advanced training in Natural, Chinese and Ayurvedic Medicines and Homeopathy. He sees patients in his Functional Integrative Medicine clinic at the base of the Tetons in Jackson Hole, WY and serves as Medical Director for The Meno Clinic Center for Advanced Medicine in Jackson Hole.

Dr. Mark Menolascino MD, MS, ABIHM, ABAARM, IFMCP, Meno Center for Advanced Medicine, http://www.menoclinic.com, +1 (307) 690-2311, [email protected]

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.